lifesciencesreview
US
APAC
EUROPE
Elypta
Karl Bergman, CEO, Elypta
Karl Bergman, CEOCancer is considered one of the leading causes of death in the world. For most people, the gold standard for diagnosis is medical imaging or biopsy. But hardly do they realize that these methods are not always useful when symptoms are inconclusive. Moreover, they are also associated with multiple risks, high costs, and a high amount of inconvenience for patients, making them ill-suited for frequently used applications, such as tracking disease progression or screening - where any undue risk must be avoided. Staying abreast of these facts, Swedenbased Elypta is offering liquid biopsies - sampling and analysis of body fluids –with an aim to provide minimally invasive, safe and convenient means of diagnosing and monitoring cancer. Being highly accurate, they also show potential for earlier cancer detection while increasing the chance of curative treatment.

In lieu of that, Elypta has developed the first-ever metabolism-based liquid biopsy platform, meant for early detection and closer follow-up of multiple cancer indications. The platform is inherently safe and convenient, and of course, exceptionally sensitive in studies to date and provides affordable assay technology. These features enable multiple potential applications of the platform that are explored across cancers. It helps in earlier detection of recurring cancer by safer, more convenient, and closer surveillance postsurgery at a time when the doctors are uncertain about the symptoms. The platform also acts as a guide for therapy by more accurate prognosis and closer monitoring of response to treatment.

Meanwhile, a major part of Elypta’s attention is focused on enabling a more accurate and efficient way to measure glycosaminoglycans. On that note, the company offers the first-of-its-kind standardized service for full spectrum glycosaminoglycan quantification using the Elypta MIRAM™ Glycosaminoglycan Kit (which is used for research use only).

Elypta: Augmenting the Scope of Cancer Detection

The method underlying the Elypta MIRAM™ Glycosaminoglycan Kit leverages ultra-high-performance liquid chromatography and tandem mass spectrometry for accurately measuring the concentration and structural composition of chondroitin sulfate (CS), heparan sulfate (HS), and hyaluronic acid (HA). The glycosaminoglycan measurements are made at a GLP-compliant central laboratory using Elypta MIRAM™ Glycosaminoglycan Kit, where measurements can be done in a wide array of research specimens, including blood, urine, cell cultures, tissues, and other biofluids.

The Elypta MIRAM™ Glycosaminoglycan Kit also makes the most of established state-of-the-art lab methods meant for glycosaminoglycan (GAG) extraction and detection for delivering reliable performance in a standardized and scalable way. The method relies on an enzymatic digestion assay that depolymerizes GAGs into disaccharides. Subsequently, disaccharides are labelled and separated by ultra-high performance liquid chromatography (UHPLC) and are detected using electrospray ionization triple-quadrupole mass spectrometry (ESI-MS/MS) through multiple reaction monitoring (MRM).

Apart from encouraging academic researchers to further expand the boundaries of standardized analysis of glycosaminoglycans for their research using Elypta MIRAM™ Glycosaminoglycan Kits, the company helps researchers in fundamental research on the causal role of GAGs in cancer initiation, evolution, or progression or related research questions. Likewise, when it comes to pre-clinical research, the company makes room for researchers to assess the role of GAGs in animal, cellular, xenograft models of cancer or related research questions. Last but not least, Elypta also encourages researches in clinical research that comprises human exploratory or validation studies in cancer and the role of GAGs as biomarkers.

For cancer-related research, the company is always open to exploring collaborative opportunities and joining hands with other bright minds to eradicate the global malice that cancer has now become. Driven by this objective to reduce cancer mortality, Elypta is set to redefine the boundaries in cancer research—with its metabolism-based approach and robust, cost-efficient solutions.